Patent · US Active

Acylglycerol acyltransferase-like protein MGAT-X1 and uses thereof

US8343745B2 · kind B2 · utility

0Cited by

0References

2Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Stefan Golz · Wetter (Ruhr), DE
Ulf Bruggemeier · Leichlingen, DE
Bernhard Weingartner · Feldkirch, DE
Andreas Geerts · Wuppertal, DE

Key dates

Filing date	Aug 31, 2010
Grant date	Jan 1, 2013
Priority date	—
Expiry date	Mar 27, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N9/1029
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.